BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31312931)

  • 21. Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab.
    Marushima H; Kimura H; Miyazawa T; Sakai H; Furuya N; Koji K; Nakamura H; Saji H
    Anticancer Drugs; 2020 Feb; 31(2):177-182. PubMed ID: 31725045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    Tsuchiya T; Kamohara R; Muraoka M; Nagayasu T; Saeki S; Takenoyama M; Suzuki M; Inada K; Tokunaga S; Hayashi T; Urabe S; Koga T; Akamine S; Sugio K
    BMC Cancer; 2020 Dec; 20(1):1192. PubMed ID: 33276755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
    Ou W; Sun HB; Ye X; Zhang BB; Yang H; Fang Q; Li P; Wang SY
    J Thorac Oncol; 2010 Jul; 5(7):1033-41. PubMed ID: 20502361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.
    Tanaka F; Yanagihara K; Otake Y; Miyahara R; Wada H
    Cancer Sci; 2004 Apr; 95(4):371-6. PubMed ID: 15072598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
    Yamaguchi M; Tada H; Mitsudomi T; Seto T; Yokoi K; Katakami N; Nakagawa K; Oda M; Ohta M; Sawa T; Yamashita M; Iked N; Saka H; Higashiyama M; Nomori H; Semba H; Negoro S; Chiba Y; Shimokawa M; Fukuoka M; Nakanishi Y;
    Int J Clin Oncol; 2021 Dec; 26(12):2216-2223. PubMed ID: 34463869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
    Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
    Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
    Okamoto I; Yoshioka H; Morita S; Ando M; Takeda K; Seto T; Yamamoto N; Saka H; Asami K; Hirashima T; Kudoh S; Satouchi M; Ikeda N; Iwamoto Y; Sawa T; Miyazaki M; Tamura K; Kurata T; Fukuoka M; Nakagawa K
    J Clin Oncol; 2010 Dec; 28(36):5240-6. PubMed ID: 21079147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
    Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
    Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.
    Pisters KM; Vallières E; Crowley JJ; Franklin WA; Bunn PA; Ginsberg RJ; Putnam JB; Chansky K; Gandara D
    J Clin Oncol; 2010 Apr; 28(11):1843-9. PubMed ID: 20231678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
    Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
    J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of induction chemotherapy with carboplatin and paclitaxel plus bevacizumab in patients with stage IIIA to IV nonsquamous non-small cell lung cancer.
    Imai K; Nakagawa T; Matsuzaki I; Orino K; Saito H; Sato K; Sano M; Nakayama K; Sato Y; Motoyama S; Nomura K; Shibata H; Minamiya Y
    Surg Today; 2019 Aug; 49(8):678-685. PubMed ID: 30826861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility Trial of Oral UFT after Platinum-based Adjuvant Chemotherapy in Patients with Resected Non-small Cell Lung Cancer.
    Sawada S; Sugimoto R; Ueno T; Yamashita M
    Acta Med Okayama; 2017 Dec; 71(6):513-518. PubMed ID: 29276224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.
    Crawford J; Swanson P; Schwarzenberger P; Sandler A; Prager D; Zhang K; Freeman DJ; Johnson CW; Krishnan K; Johnson D
    J Thorac Oncol; 2013 Dec; 8(12):1510-8. PubMed ID: 24389433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC).
    Kaplan B; Altýnbas M; Eroglu C; Karahacioglu E; Er O; Ozkan M; Bilgin M; Canoz O; Gulmez I; Gulec M
    Am J Clin Oncol; 2004 Dec; 27(6):603-10. PubMed ID: 15577439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
    Yamashita Y; Kataoka K; Ishida T; Matsuura M; Seno N; Mukaida H; Miyahara E; Miyata Y; Okita R; Shimizu K; Watari M; Okumichi T; Okada M
    J Thorac Oncol; 2008 Jun; 3(6):612-6. PubMed ID: 18520800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. UFT plus carboplatin for head and neck cancer.
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M; Tomita T; Yamashita T
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):72-5. PubMed ID: 11098499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
    Miyoshi T; Kondo K; Toba H; Yoshida M; Fujino H; Kenzaki K; Sakiyama S; Takehisa M; Tangoku A
    Anticancer Res; 2007; 27(4C):2641-8. PubMed ID: 17695427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.